Yasheng Zhu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10110392/publications.pdf

Version: 2024-02-01

18	1,789	16	19
papers	citations	h-index	g-index
19	19	19	3352
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR. Communications Biology, 2022, 5, 182.	4.4	10
2	ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression. Cell Death and Differentiation, 2022, 29, 1611-1624.	11.2	5
3	SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions. Molecular Cancer, 2021, 20, 100.	19.2	36
4	The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA. International Journal of Cancer, 2020, 146, 475-486.	5.1	27
5	Novel Long Non-coding RNA IncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression. Molecular Therapy, 2020, 28, 2473-2487.	8.2	33
6	Heterogeneity of PTEN and PPARâ€Î³ in cancer and their prognostic application to bladder cancer. Experimental and Therapeutic Medicine, 2019, 18, 3177-3183.	1.8	8
7	Prostatic Acid Phosphatase (PAP) Predicts Prostate Cancer Progress in a Population-Based Study: The Renewal of PAP?. Disease Markers, 2019, 2019, 1-10.	1.3	23
8	Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. Molecular Cancer, 2019, 18, 170.	19.2	79
9	SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Developmental Cell, 2019, 48, 329-344.e5.	7.0	53
10	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. European Urology, 2018, 73, 322-339.	1.9	130
11	Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance. Nature, 2018, 553, 91-95.	27.8	660
12	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation. Nature Medicine, 2017, 23, 1055-1062.	30.7	225
13	A feed-forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression. Cancer Letters, 2016, 374, 62-74.	7.2	64
14	SPOP E3ÂUbiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. Cell Reports, 2015, 13, 1183-1193.	6.4	55
15	Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 384.e9-384.e20.	1.6	25
16	Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Molecular Cell, 2015, 59, 904-916.	9.7	129
17	Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. Oncotarget, 2015, 6, 40611-40621.	1.8	17
18	Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget, 2014, 5, 11091-11102.	1.8	160